Anti-Ia antibody in the sera of normal subjects after in vivo antigenic stimulation

K. Okudaira, James Goodwin, R. C. Williams

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We showed that sera from normal subjects after antigenic challenge with intradermal PPD or Candida antigens or with subcutaneous tetanus vaccine contain a factor that blocks the binding of mouse monoclonal anti-Ia antibody to Ia-positive T cells or to B35 M cells, an Ia-positive human B cell line. The blocking activity appears 48 to 72 h after antigenic challenge and is gone by day 7. The appearance of the anti-Ia blocking activity coincided with a drop in the percentage of Ia-positive T cells and non-T cells in the peripheral blood of these subjects and also with a decrease in the density of surface Ia on the non-T cell population. The blocking was not genetically restricted; that is, serum from a given subject blocked anti-Ia binding to Ia-positive T cells of subjects with different DR haplotypes. The blocking activity was contained in the IgM fraction of the sera. The blocking activity of the sera was eliminated after absorption of the sera with Ia-positive but not with Ia-negative human cell lines. It would appear, therefore, that the blocking of monoclonal anti-Ia binding is caused by an IgM anti-Ia antibody that appears in normals after in vivo antigenic challenge.

Original languageEnglish (US)
Pages (from-to)255-267
Number of pages13
JournalJournal of Experimental Medicine
Volume156
Issue number1
StatePublished - 1982
Externally publishedYes

Fingerprint

Anti-Idiotypic Antibodies
Serum
T-Lymphocytes
Immunoglobulin M
Cell Line
Tetanus Toxoid
Tuberculin
Candida
Haplotypes
B-Lymphocytes
Monoclonal Antibodies
Antigens
Population

ASJC Scopus subject areas

  • Immunology

Cite this

Anti-Ia antibody in the sera of normal subjects after in vivo antigenic stimulation. / Okudaira, K.; Goodwin, James; Williams, R. C.

In: Journal of Experimental Medicine, Vol. 156, No. 1, 1982, p. 255-267.

Research output: Contribution to journalArticle

@article{2bc910796ad742fda3199a2f02b1c3ee,
title = "Anti-Ia antibody in the sera of normal subjects after in vivo antigenic stimulation",
abstract = "We showed that sera from normal subjects after antigenic challenge with intradermal PPD or Candida antigens or with subcutaneous tetanus vaccine contain a factor that blocks the binding of mouse monoclonal anti-Ia antibody to Ia-positive T cells or to B35 M cells, an Ia-positive human B cell line. The blocking activity appears 48 to 72 h after antigenic challenge and is gone by day 7. The appearance of the anti-Ia blocking activity coincided with a drop in the percentage of Ia-positive T cells and non-T cells in the peripheral blood of these subjects and also with a decrease in the density of surface Ia on the non-T cell population. The blocking was not genetically restricted; that is, serum from a given subject blocked anti-Ia binding to Ia-positive T cells of subjects with different DR haplotypes. The blocking activity was contained in the IgM fraction of the sera. The blocking activity of the sera was eliminated after absorption of the sera with Ia-positive but not with Ia-negative human cell lines. It would appear, therefore, that the blocking of monoclonal anti-Ia binding is caused by an IgM anti-Ia antibody that appears in normals after in vivo antigenic challenge.",
author = "K. Okudaira and James Goodwin and Williams, {R. C.}",
year = "1982",
language = "English (US)",
volume = "156",
pages = "255--267",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - Anti-Ia antibody in the sera of normal subjects after in vivo antigenic stimulation

AU - Okudaira, K.

AU - Goodwin, James

AU - Williams, R. C.

PY - 1982

Y1 - 1982

N2 - We showed that sera from normal subjects after antigenic challenge with intradermal PPD or Candida antigens or with subcutaneous tetanus vaccine contain a factor that blocks the binding of mouse monoclonal anti-Ia antibody to Ia-positive T cells or to B35 M cells, an Ia-positive human B cell line. The blocking activity appears 48 to 72 h after antigenic challenge and is gone by day 7. The appearance of the anti-Ia blocking activity coincided with a drop in the percentage of Ia-positive T cells and non-T cells in the peripheral blood of these subjects and also with a decrease in the density of surface Ia on the non-T cell population. The blocking was not genetically restricted; that is, serum from a given subject blocked anti-Ia binding to Ia-positive T cells of subjects with different DR haplotypes. The blocking activity was contained in the IgM fraction of the sera. The blocking activity of the sera was eliminated after absorption of the sera with Ia-positive but not with Ia-negative human cell lines. It would appear, therefore, that the blocking of monoclonal anti-Ia binding is caused by an IgM anti-Ia antibody that appears in normals after in vivo antigenic challenge.

AB - We showed that sera from normal subjects after antigenic challenge with intradermal PPD or Candida antigens or with subcutaneous tetanus vaccine contain a factor that blocks the binding of mouse monoclonal anti-Ia antibody to Ia-positive T cells or to B35 M cells, an Ia-positive human B cell line. The blocking activity appears 48 to 72 h after antigenic challenge and is gone by day 7. The appearance of the anti-Ia blocking activity coincided with a drop in the percentage of Ia-positive T cells and non-T cells in the peripheral blood of these subjects and also with a decrease in the density of surface Ia on the non-T cell population. The blocking was not genetically restricted; that is, serum from a given subject blocked anti-Ia binding to Ia-positive T cells of subjects with different DR haplotypes. The blocking activity was contained in the IgM fraction of the sera. The blocking activity of the sera was eliminated after absorption of the sera with Ia-positive but not with Ia-negative human cell lines. It would appear, therefore, that the blocking of monoclonal anti-Ia binding is caused by an IgM anti-Ia antibody that appears in normals after in vivo antigenic challenge.

UR - http://www.scopus.com/inward/record.url?scp=0019956256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019956256&partnerID=8YFLogxK

M3 - Article

VL - 156

SP - 255

EP - 267

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -